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internalization of neurokinin-1 receptors at the spinal 
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Background: To identify a new strategy for postoperative pain management, we investigated the analgesic 
effects of allopregnanolone (Allo) in an incisional pain model, and also assessed its effects on the activities 
of the primary afferent fibers at the dorsal horn.
Methods: In experiment 1, 45 rats were assigned to Control, Allo small-dose (0.16 mg/kg), and Allo large-dose 
(1.6 mg/kg) groups (n = 15 in each). The weight bearing and mechanical withdrawal thresholds of the hind 
limb were measured before and at 2, 24, 48, and 168 h after Brennan’s surgery. In experiment 2, 16 rats were 
assigned to Control and Allo (0.16 mg/kg) groups (n = 8 in each). The degree of spontaneous pain was 
measured using the grimace scale after the surgery. Activities of the primary afferent fibers in the spinal cord 
(L6) were evaluated using immunohistochemical staining.
Results: In experiment 1, the withdrawal threshold of the Allo small-dose group was significantly higher than 
that of the Control group at 2 h after surgery. Intergroup differences in weight bearing were not significant. 
In experiment 2, intergroup differences in the grimace scale scores were not significant. Substance P release 
in the Allo (0.16 mg/kg) group was significantly lower than that in the Control group.
Conclusions: Systemic administration of Allo inhibited mechanical allodynia and activities of the primary 
afferent fibers at the dorsal horn in a rat postoperative pain model. Allo was proposed as a candidate for 
postoperative pain management. (Korean J Pain 2018; 31: 10-5)
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INTRODUCTION
Significant improvement has been made in the manage-
ment of postoperative pain. However, many patients still 
experience discomfort and side effects resulting in distress, 
higher morbidity, and prolonged hospital stays [1-3]. 
Allopregnanolone (Allo), a neurosteroid, has been shown to 
exert beneficial effects on pain behaviors or sensitivities 
in various neuropathic pain models and painful conditions 
[4-12]. However, to date, there has been no report ad-
dressing the effects of Allo in postoperative pain models.
Kawano et al. [11] reported lower Allo concentrations 
in the spinal cord of hyperalgesic rats than in those of 
non-hyperalgesic rats, but not in the brain or serum. 
Furthermore, intrathecal exogeneous administration of Allo 
resulted in anti-hyperalgesic effects in hyperalgesic rats 
following spinal nerve ligation. Therefore, the spinal cord 
was suggested as an important site for the anti-noci-
ceptive effects of Allo. On the other hand, substance P 
specifically binds to neurokinin-1 receptors (NK-1r) in the 
superficial dorsal horn (lamine I and II), causing receptor 
internalization. This NK-1r internalization is considered as 
an index of extracellular substance P release from primary 
afferents and reflects the degree of the primary afferent 
fiber activities in the spinal dorsal horn. Moreover, NK-1r 
internalization can be visualized using immunohistochemistry 
as a quantitative assay for neurotransmitter release 
[13-15].
In the present study, we investigated the effects of 
Allo in Brennane’s postoperative pain model [16], and also 
assessed its effects on the activity of the primary afferent 
fibers in the spinal dorsal horn using immunohisto-
chemistry.
MATERIALS AND METHODS
This study was approved by the Institutional Animal Care 
and Use Committee at the University of Tsukuba. A total 
of 61 male Sprague-Dawleyrats (SLC Ltd, Japan) were used 
in this study. They were housed under standard conditions 
(room temperature 24°C, 14/10 h light/dark cycle) with ad 
labium access to food and water. A 1-week acclimation 
period was allowed after arrival at the facility. 
Allopregnanolone (5-pregnane-5-ol-20-one) sul-
fate was purchased from Steraloids Inc. (Newport, RI). The 
vehicle solution for Allo contained 5% polysorbate 80 (Wako 
Pure Chemical Ind. Ltd., Japan) and 16% polyethylene gly-
col (Sigma, MO) in physiological saline. Allo or vehicle was 
injected subcutaneously, under the skin of the back, at a 
volume of 1 ml/kg.
The rat hind paw plantar incision model of post-
operative pain was used as previously described [16]. Under 
2.5% isoflurane anesthesia, a 1.0 cm longitudinal incision 
was made with a No. 11 scalpel 0.5 cm from the end of 
the heel to the base of the toes. After elevation of the 
flexor tendon, the incision was closed with two mattress 
sutures of 5-0 nylon on a FS-2 needle. The animals were 
allowed to recover from general anesthesia in a cage.
1. Experiment 1
Forty-five rats, weighing 222 ± 13 g at the start of the 
experiment, were assigned randomly to the Control, Allo 
small-dose (0.16 mg/kg), or Allo large-dose (1.6 mg/kg) 
group (n = 15 per group). Fifteen minutes before the sur-
gery, each rat received an injection of the vehicle solution 
or designated dose of Allo. The dose of Allo was selected 
according to the report of Ocvirk et al. [7]. 
Hind limb weight bearing and mechanical withdrawal 
thresholds were measured before surgery (0 h), and at 2, 
24, 48, and 168 h after surgery. The unrestrained animals 
were placed on an elevated plastic mesh floor (grid 12 × 
12 mm) under a clear cage (21 × 21 × 15 cm) and allowed 
to acclimate for 15 min. Each animal was closely observed 
during a 1-min period. The scores were given depending 
on the position in which the foot was found during the 
scoring period: a score of 0 if the foot was completely off 
the mesh, a score of 1 if the area of the wound touched 
the mesh without bearing weight, and a score of 2 if the 
animal put full weight on the foot. The weight bearing 
score was calculated with the sum of each score × time 
(sec).
Withdrawal responses to mechanical stimulation were 
subsequently determined using von Frey filaments (Stoelting, 
Wood Dale, IL, USA) applied from underneath the cage 
through an opening in the mesh floor to an area adjacent 
to the wound. The von Frey set consists of 10 filaments 
(0.4, 0.6, 1.0, 1.4, 2.0, 4.0, 6.0, 8.0, 10.0, and 15.0 g), 
and the testing is initiated with the 2 g filament. In the 
absence of a paw withdrawal response (negative response) 
to the initially selected filament, a stronger stimulus was 
presented; in the event of an initial paw withdrawal 
(positive response), the next weaker stimulus was chosen. 
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In cases where continuous positive or negative responses 
were observed to the exhaustion of the stimulus set, values 
of 0.4 g and 15 g were assigned respectively. The up-down 
method was used to record the threshold [17].
2. Experiment 2
Sixteen rats, weighing 260 ± 14 g, were assigned ran-
domly to either the Control or Allo group (n = 8 per group). 
Fifteen minutes before the plantar incision, each rat re-
ceived an injection of vehicle solution or Allo (0.16 mg/kg). 
At 40 m after the surgery, spontaneous pain degree 
was measured using the rat grimace scale [18]. The gri-
mace scale consists of the observation of four action units 
(orbital tightening, nose/cheek flattening, ear changes, 
and whisker changes) and ranges from 0 (pain free) to 8 
(most severe).
At 45 m after the surgery, rats were deeply anes-
thetized with an intraperitoneal injection of 5% pento-
barbital (150 mg/kg) and perfused transcardially with 500 
ml of 0.1M phosphate buffered saline (PBS, pH 7.4). 
Subsequently, the fixation was carried out with 500 ml of 
4% formaldehyde in PBS. 
The lumbar spinal cord was rapidly dissected and 
postfixed in the same fixation solution for 2 h After cry-
oprotective treatment, the spinal segment L6 was cut into 
30-m transverse slices at intervals of 300 m with a 
cryostat (Leica, Germany) and analyzed by fluorescence 
immunohistochemistry as described previously, with minor 
modifications [19]. Six sections per animal were labeled 
with primary antiserum, rabbit anti-NK-1r (1:3,000; 
Advanced Targeting Systems, San Diego, CA) and mouse 
anti-NeuN (1:1,000, Millipore, Temecula, CA) in PBS con-
taining 10% normal goat serum and 0.2% Triton-X for 18 
h at room temperature. After a rinse in PBS, sections were 
incubated in secondary antibodies, Alexa Fluor 488 Goat 
anti-rabbit IgG (1:1,000, A11008, Life Technology Japan 
Ltd., Tokyo, Japan) and Alexa Fluor 594 Goat anti-mouse 
IgG (1:1,000, A-11032, Life Technology Japan Ltd., Tokyo, 
Japan) in PBS for 2 h at room temperature. All sections 
were finally rinsed in PBS, mounted on glass slides, and 
covered with a coverslip using ProLong Gold Antifade 
Reagent (Life Technology Japan Ltd., Tokyo, Japan).
Six NeuN-positive cells per section were randomly se-
lected in each side of the dorsal horn (lamina I) and NK-1r 
internalization was counted at X300 magnification using 
an Olympus fluorescence microscope (FLUOVIEW FV10i, 
Olympus Corporation, Tokyo, Japan). Data collection was 
performed by two authors blinded to the treatment (vehicle 
or Allo) during the behavioral testing and microscopic 
examination. Treatment status was subsequently exposed 
and statistically analyzed.
3. Statistical analysis
Pain score and mechanical allodynia were analyzed by us-
ing the Kruskal-Wallis test (followed by Steel’s test) and 
Wilcoxon’s signed rank test. Body weight was analyzed us-
ing analysis of variance (ANOVA) and repeated-measures 
ANOVA. Grimace score and cell number of positive-in-
ternalization were analyzed by using the Mann-Whitney 
U-test and Fisher exact test, respectively. The level of 
significance was set at P ＜ 0.05.
RESULTS
1. Experiment 1
At the end of the protocol, the body weights of the animals 
in the three experimental groups were comparable: the 
Control group, 306 ± 62 g; the Allo small-dose group, 310 ± 
54 g; and the Allo large-dose group, 302 ± 63 g. There 
was no significant difference in weight increment among 
the three groups.
The weight bearing scores of all the groups decreased 
at 2, 24, and 48 h after surgery (P ＜ 0.05 vs 0 h) and 
returned to the pre-incision level at the end of the study 
(168 h). There were no significant differences in the weight 
bearing scores among the three experimental groups at 
any time point (Table 1). 
The withdrawal threshold in the incised foot decreased 
after the incision in all the groups, but not in the Allo 
large-dose group at 168 h, (P ＜ 0.05 vs 0 h; Fig. 1). The 
withdrawal threshold of the Allo small-dose group was sig-
nificantly higher than that of the Control group at 2 h after 
the surgery (P ＜ 0.05; Fig. 1).
2. Experiment 2
The median (25-75%) grimace scales of the Control and 
Allo groups were 5 (2-6.3) and 4 (1.5-5), respectively. 
There was no significant difference in the grimace scale 
between the two groups.
Unilateral hind paw plantar incision produced a robust 
NK-1r internalization in the ipsilateral superficial dorsal 
horn, but not the contralateral dorsal horn (ipsilateral 
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Table 1. Weight Bearing Score
0 2 24 48 168 hr
Control 120 60 (0–120)* 73 (57–120)* 79 (60–120)* 120 (101–120)
Allo-Small 120 80 (0–120)* 87 (60–120)* 107 (13–120)* 120 (75–120)
Allo-Large 120 60 (49–120)* 60 (34–120)* 81 (0–120)* 120 (60–120)
Allo-Small: allopregnanolone 0.16 mg/kg, Allo-Large: allopregnanolone 1.6 mg/kg median (min–max). There was no significant difference
among three groups. *P ＜ 0.05 vs 0 h. 
Fig. 1. Summary of withdrawal thresholds to von Frey fila-
ments before and after surgery. The results are expressed
as medians with 1st and 3rd quartiles, and 10th and 90th
percentiles. White column: Control group, Light gray 
column: Allopregnanolone 0.16 mg/kg group, Dark gray 
column: Allopregnanolone 1.6 mg/kg group. *P ＜ 0.05 
(Control vs Allopregnanolone 0.16 mg/kg group) by 
Kruskal-Wallis test and Steel’s test. #P ＜ 0.05 (vs 
pre-incision values) by Wilcoxon’s signed rank test.
Fig. 2. Positive cell number of neurokinin-1 receptor (Nk-1r)
internalization (gray column) and total observation cell 
number (gray + white column) at 45 minutes after surgery.
Cont: Control group, Allo: allopregnanolone (0.16 mg/kg) 
group. *P ＜ 0.05 vs Control group, #P ＜ 0.05 vs Con-
tralateral side by Fisher exact test.
Fig. 3. Representative confocal fluorescent microscopic 
images of neurokinin-1 receptor (NK-1r) and NeuN at L6 
lumbar spinal dorsal horn from incision model rats. Green: 
NK-1r, Red: NeuN. (A) An image of NK-1r in the lamina I. 
Notice the presence of NK-1r on a neuron membrane and 
the lack of NK-1r containing endosomes in the cytoplasm. 
(B) An image of incision-induced NK-1r internalization. 
Notice the presence of NK-1r containing endosomes in the
cytoplasm. Scale bar is 10 m.
104/287, contralateral 15/252; P ＜ 0.05). 
Allo (0.16 mg/kg) injection resulted in a significant re-
duction in the ipsilateral increase in plantar incision- 
evoked NK-1r internalization (ipsilateral 81/282, con-
tralateral 11/258; P ＜ 0.05; Fig. 2). Fig. 3 depicts a typical 
NK-1r internalization negative cell (A) and positive cell (B).
DISCUSSION
Systemic administration of Allo (0.16 mg/kg) alleviated 
mechanical allodynia at 2 h after incision of the hind paw 
plantar. This result is in line with previous reports, which 
investigated the effects of Allo in neuropathic pain models 
and naive animals [5,6,8,10,11]. The anti-allodynic effects 
of Allo were not dose-dependent in this study; this finding 
is also in agreement with those of previous studies [4,7]. 
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The biphasic anti-allodynic effects of Allo implies that 
more than one mechanism and/or multiple sites of action 
may be involved. Allo is known to modulate plural channels 
and receptors such as gamma-amino butyric acid A 
(GABAA) and glycine receptors as well as L- and T-type 
calcium channels [20-22]. Allo induced analgesia is medi-
ated by both T-type calcium and GABAA channels [22]. 
Some literatures report that L-type calcium channel 
blockers prevent hyperalgesia in chemotherapy-induced 
neuropathy or opioid-induced hyperalgesia models [23,24]. 
In other words, the activation of L-type calcium channels 
may decrease Allo induced anti-hyperalgesic effects under 
some conditions. 
On the other hand, Allo stimulates GABA receptors at 
multiple sites of the nervous system. One potential site of 
action of GABA agonist is in the dorsal horn of the spinal 
cord, where GABA suppresses afferent nociceptive input 
[25]. However, GABA is also involved in the regulation of 
descending pain modulatory pathways originating from the 
rostroventral medulla (RVM) and periaqueductal gray (PAG). 
Increasing GABA-ergic tone at these sites has pronoci-
ceptive effects [26,27]. Thus, the analgesic effects of Allo 
might be inhibited by decreasing the tonic descending in-
hibition from the RVM and PAG at higher doses.
In the large dose (1.6 mg/kg) Allo group, no significant 
differences in the withdrawal threshold were found between 
the pre-surgery measurement and 168 h after surgery. 
This might be due to the neuroprotective effects of Allo 
[4,28]. Allo is reported to increase proliferation of rodent 
and human neural progenitor cells in vitro via GABAA re-
ceptor and L-type calcium channel-dependent mechanism 
[29]. Chronic post-surgical pain remains a major clinical 
problem and its incidence is reported to range between 10 
and 50% [30,31]. This result might influence the problem 
of chronic post-surgical pain.
There was no significant difference in the weight bear-
ing score among the three experimental groups. We 
speculated that the weight bearing score might be affected 
by the learning ability of the rats. Thus, we selected the 
grimace score in experiment 2. However, no significant 
differences were detected between the Allo and Control 
groups. The spontaneous pain in the incision model might 
be lower than that of other pain models with nerve 
damage. Since NK-1r internalization disappeared in about 
30 min [14], we measured the grimace scale at only one 
point. This might be another reason for the negative result 
of the grimace scale in this study. 
Allo decreased the plantar incision-evoked NK-1r in-
ternalization in the dorsal horn (lamina I), which implies the 
inhibition of substance P release from the primary afferent 
fiber. The decrease of NK-1r internalization was specu-
lated to be due to Allo-induced facilitation of the GABAA 
receptor in the spinal dorsal horn and presynaptic in-
hibition of substance P release from the primary afferent 
terminal [32,33]. The decreased release of substance P is 
in accord with the anti-allodynia effect of Allo.
In conclusion, systemic administration of Allo alle-
viated mechanical allodynia in a rat postoperative pain 
model. Inhibition of NK-1r internalization was observed in 
the dorsal horn (lamina I) of rats treated with Allo. Our 
findings propose the therapeutic potential of Allo in the 
postoperative pain management, however, further inves-
tigations will be necessary to address its clinical 
usefulness.
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